Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMortgage Advice Bureau Regulatory News (MAB1)

Share Price Information for Mortgage Advice Bureau (MAB1)

Share Price is delayed by 15 minutes
Get Live Data
529.00    4.00 (0.76%)
Bid:
528.00
Ask:
533.00
Spread: 5.00 (0.947%)
Market Cap: £304.40m
MAB1 Live PriceLast checked at - London Stock Exchange

Intraday Mortgage Advice Bureau Share Chart

Trading Update

25 Jul 2024 07:00

RNS Number : 7494X
Mortgage Advice Bureau (Hldgs) PLC
25 July 2024
 

25 July 2024

Mortgage Advice Bureau (Holdings) plc 

("MAB" or the "Group")

Trading Update 

Mortgage Advice Bureau (Holdings) plc (AIM: MAB1) today issues a trading update for the six months ended 30 June 2024, ahead of publishing interim results on 24 September 2024.

Group revenue for the six months ended 30 June 2024 increased by 5% to £123.5m (H1 2023: £117.5m), despite a difficult market backdrop, with UK Finance forecasting there would be a 5% reduction in gross lending in 2024 to £215 bn (2023 gross lending was £226 bn).

MAB also increased its value of gross mortgage completions by 5% and our market share gains were maintained throughout the five months ended 31 May 2024 (the latest available data period), with MAB's share of new lending increasing to 8.2% versus 8.0% for the equivalent timeframe last year.

The average number of mainstream advisers in the first half fell 3% to 1,898 (H1 2023: 1,966), with our adviser numbers having increased following the period end to 1,944 (2023:1,918). 

As expected, we saw a slight dip in the organic number of advisers in H1. Although forecast interest rate reductions have not yet materialised, we are now starting to see that trend reverse. In addition, new advisers from Appointed Representative ("AR") recruitment have started to come through in a more meaningful way since the period end.

We expect to deliver further growth in the remainder of this year as new ARs are recruited into MAB, and our ARs start growing adviser numbers again after more than 20 months of consolidation that reflected market conditions.

Current Trading and Outlook

The Group is trading in line with expectations, with a modest pick-up in activity expected in the second half.

There is a significant amount of re-financing that has been delayed for several months, pending possible rate reductions in the summer. Whilst the market may no longer expect a rate cut in August, at some stage we expect these borrowers will want to switch to a better mortgage rate, rather than sitting on expensive floating rates. The current market expectation is that the Bank of England will cut rates by c. 0.5% by the end of the year.

2024 was always going to be about stability, following an extremely challenging 2023, with momentum building in the latter part of the year and into 2025. We expect base rate reductions to be the trigger for a recovery in housing transactions and a gradual release of pent-up demand.

Peter Brodnicki, CEO of MAB, commented:

"2024 started well, following a difficult 2023. However, most experts have been proved wrong in terms of the pace and scale of any rate reductions this year, and that has consequently delayed many re-finance transactions in H1 and any sustainable pick up in purchase activity.

"Against this challenging backdrop, I am very pleased with how MAB continues to grow its market share. As we did last year, to ensure we are in the best possible shape when market conditions improve, we have continued to invest in technology to drive lead flow and adviser productivity across the Group. The progress we are making will further increase our resilience in more challenging market conditions, whilst supporting accelerated growth when market conditions normalise.

"We look forward to a downward trend in the base rate, which will lead to a more active refinancing market and a build-up to more normal levels of housing transactions. It is very encouraging to now have a new government so focused on housebuilding and other initiatives that will give our market and MAB a tailwind, added to which we expect to see record years in terms of re-financing in 2025/26.

We therefore expect to see activity pick up in the second half of the year and into 2025, when we anticipate our investment in lead generation and retention will contribute more significantly to our ambitious growth plans."

 

Enquiries:

Mortgage Advice Bureau (Holdings) plc +44 (0)1332 525007

Peter Brodnicki, Chief Executive Officer

Ben Thompson, Deputy Chief Executive Officer

Emilie McCarthy, Chief Financial Officer

Nominated Adviser and Joint Broker +44 (0)20 7260 1000

Deutsche Numis

Daniel Werchola / Giles Rolls

Joint Broker +44 (0) 20 7418 8900

Peel Hunt LLP

Andrew Buchanan

 

Media Enquiries:

investorrelations@mab.org.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTLZLLLZDLZBBE
Date   Source Headline
28th Feb 202010:04 amRNSDirector/PDMR Shareholding
26th Feb 20204:41 pmRNSSecond Price Monitoring Extn
26th Feb 20204:35 pmRNSPrice Monitoring Extension
17th Feb 202010:34 amRNSDirector/PDMR Shareholding
3rd Feb 20204:40 pmRNSSecond Price Monitoring Extn
3rd Feb 20204:35 pmRNSPrice Monitoring Extension
3rd Feb 20202:13 pmRNSHolding(s) in Company
31st Jan 202012:23 pmRNSDirector/PDMR Shareholding
28th Jan 20207:00 amRNSTrading Update
14th Jan 20205:46 pmRNSDirector/PDMR Shareholding
31st Dec 20199:23 amRNSDirector/PDMR Shareholding
16th Dec 20194:13 pmRNSDirector/PDMR Shareholding
12th Dec 201910:18 amRNSBlock listing Interim Review
2nd Dec 20197:00 amRNSDirector/PDMR Shareholding
14th Nov 20193:05 pmRNSDirector/PDMR Shareholding
31st Oct 201912:34 pmRNSDirector/PDMR Shareholding
25th Oct 20194:02 pmRNSDirector/PDMR Shareholding
22nd Oct 20195:13 pmRNSHolding(s) in Company
22nd Oct 20195:09 pmRNSHolding(s) in Company
14th Oct 20194:31 pmRNSDirector/PDMR Shareholding
30th Sep 20193:18 pmRNSHolding(s) in Company
30th Sep 20193:13 pmRNSDirector/PDMR Shareholding
24th Sep 20197:00 amRNSHalf-year Report
17th Sep 20196:25 pmRNSDirector/PDMR Shareholding
30th Aug 20192:22 pmRNSDirector/PDMR Shareholding
29th Aug 201912:07 pmRNSSecond Price Monitoring Extn
29th Aug 201912:02 pmRNSPrice Monitoring Extension
27th Aug 201912:07 pmRNSSecond Price Monitoring Extn
27th Aug 201912:02 pmRNSPrice Monitoring Extension
23rd Aug 201912:07 pmRNSSecond Price Monitoring Extn
23rd Aug 201912:02 pmRNSPrice Monitoring Extension
22nd Aug 201912:07 pmRNSSecond Price Monitoring Extn
22nd Aug 201912:02 pmRNSPrice Monitoring Extension
21st Aug 201912:07 pmRNSSecond Price Monitoring Extn
21st Aug 201912:02 pmRNSPrice Monitoring Extension
20th Aug 201912:07 pmRNSSecond Price Monitoring Extn
20th Aug 201912:02 pmRNSPrice Monitoring Extension
19th Aug 201912:07 pmRNSSecond Price Monitoring Extn
19th Aug 201912:02 pmRNSPrice Monitoring Extension
14th Aug 20194:07 pmRNSDirector/PDMR Shareholding
13th Aug 201912:07 pmRNSSecond Price Monitoring Extn
13th Aug 201912:02 pmRNSPrice Monitoring Extension
7th Aug 20199:06 amRNSReplacement: Director/PDMR Shareholding
31st Jul 20195:46 pmRNSDirector/PDMR Shareholding
31st Jul 201912:07 pmRNSSecond Price Monitoring Extn
31st Jul 201912:02 pmRNSPrice Monitoring Extension
29th Jul 201912:07 pmRNSSecond Price Monitoring Extn
29th Jul 201912:02 pmRNSPrice Monitoring Extension
26th Jul 201912:07 pmRNSSecond Price Monitoring Extn
26th Jul 201912:02 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.